Nørgaard JM - Search Results

1

Reasons for treating secondary AML as de novo AML.

Ostgård LS, Kjeldsen E, Holm MS, Brown Pde N, Pedersen BB, Bendix K, Johansen P, Kristensen JS, Nørgaard JM. Ostgård LS, et al. Among authors: norgaard jm. Eur J Haematol. 2010 Sep;85(3):217-26. doi: 10.1111/j.1600-0609.2010.01464.x. Epub 2010 Apr 29. Eur J Haematol. 2010. PMID: 20456491

2

Relation of blast cell survival and proliferation to chemotherapy resistance in AML.

Nørgaard JM, Langkjer ST, Palshof T, Clausen N, Pedersen B, Hokland P. Nørgaard JM, et al. Br J Haematol. 1996 Jun;93(4):888-97. doi: 10.1046/j.1365-2141.1996.d01-1735.x. Br J Haematol. 1996. PMID: 8703822

3

MDR1 gene expression and drug resistance of AML cells.

Nørgaard JM, Bukh A, Langkjer ST, Clausen N, Palshof T, Hokland P. Nørgaard JM, et al. Br J Haematol. 1998 Mar;100(3):534-40. doi: 10.1046/j.1365-2141.1998.00593.x. Br J Haematol. 1998. PMID: 9504636 Free article.

4

Trisomy 10 survival: a literature review and presentation of seven new cases.

Pedersen B, Andersen CL, Søgaard MM, Nørgaard JM, Koch J, Krejci K, Brandsborg M, Clausen N. Pedersen B, et al. Among authors: norgaard jm. Cancer Genet Cytogenet. 1998 Jun;103(2):130-2. doi: 10.1016/s0165-4608(97)00387-7. Cancer Genet Cytogenet. 1998. PMID: 9614911 Review.

5

Relevance of in vitro leukaemia cell survival to short- and long term clinical outcome in AML.

Nørgaard JM, Jensen PD, Bendix K, Clausen N, Palshof T. Nørgaard JM, et al. Leuk Lymphoma. 1999 Jan;32(3-4):327-37. doi: 10.3109/10428199909167393. Leuk Lymphoma. 1999. PMID: 10037030 Clinical Trial.

6

Leukaemia cell drug resistance and prognostic factors in AML.

Nørgaard JM, Olesen G, Kristensen JS, Pedersen B, Hokland P. Nørgaard JM, et al. Eur J Haematol. 1999 Oct;63(4):219-24. doi: 10.1111/j.1600-0609.1999.tb01881.x. Eur J Haematol. 1999. PMID: 10530409

7

Many unbalanced translocations show duplication of a translocation participant. Clinical and cytogenetic implications in myeloid hematologic malignancies.

Pedersen B, Nørgaard JM, Pedersen BB, Clausen N, Rasmussen IH, Thorling K. Pedersen B, et al. Among authors: norgaard jm. Am J Hematol. 2000 Jul;64(3):161-9. doi: 10.1002/1096-8652(200007)64:3<161::aid-ajh4>3.0.co;2-q. Am J Hematol. 2000. PMID: 10861810 Free article.

8

Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.

Nørgaard JM, Langkjer ST, Palshof T, Pedersen B, Hokland P. Nørgaard JM, et al. Eur J Haematol. 2001 Mar;66(3):160-7. doi: 10.1034/j.1600-0609.2001.00361.x. Eur J Haematol. 2001. PMID: 11350484

9

FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.

Nørgaard JM, Olesen LH, Olesen G, Meyer K, Kristensen JS, Bendix K, Pedersen B, Kjeldsen E, Hokland P. Nørgaard JM, et al. Eur J Haematol. 2001 Oct;67(4):221-9. doi: 10.1034/j.1600-0609.2001.00553.x. Eur J Haematol. 2001. PMID: 11860442

10

Validation and clinical implication of a quantitative real-time PCR determination of MDR1 gene expression: comparison with semi-quantitative PCR in 101 patients with acute myeloid leukemia.

Olesen LH, Nørgaard JM, Pallisgaard N, Bukh A, Hokland P. Olesen LH, et al. Among authors: norgaard jm. Eur J Haematol. 2003 May;70(5):296-303. doi: 10.1034/j.1600-0609.2003.00060.x. Eur J Haematol. 2003. PMID: 12694165

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

47 results

Search Page